Diffuse palmoplantar keratoderma
MONDO:0017666Palmoplantar keratoderma that diffusely involves most of the palm and sole and is caused by a genetic abnormality.
Also known as: diffuse PPK, diffuse keratosis palmoplantaris, diffuse palmoplantar hyperkeratosis
12 clinical trials for this condition and its sub-types, 0 tagged with Diffuse palmoplantar keratoderma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Diffuse palmoplantar keratoderma
-
Papillon-Lefevre disease 5 trials
-
Odonto-onycho-dermal dysplasia 2 trials
-
Bart-Pumphrey syndrome 0 trials
-
CEDNIK syndrome 0 trials
-
Clouston syndrome 0 trials
-
Haim-Munk syndrome 0 trials
-
KID syndrome 0 trials
-
Schöpf-Schulz-Passarge syndrome 0 trials
-
Dermatopathia pigmentosa reticularis 0 trials
-
Erythrokeratodermia variabilis 0 trials
8 sub-types
- Erythrokeratodermia variabilis et progressiva 1 0 trials
- Erythrokeratodermia variabilis et progressiva 2 0 trials
- Erythrokeratodermia variabilis et progressiva 3 0 trials
- Erythrokeratodermia variabilis et progressiva 4 0 trials
- Erythrokeratodermia variabilis et progressiva 5 0 trials
- Erythrokeratodermia variabilis et progressiva 6 0 trials
- Erythrokeratodermia variabilis et progressiva 7 0 trials
- Transgrediens et progrediens palmoplantar keratoderma 0 trials
-
Hearing loss with skin disease 0 trials
-
Loricrin keratoderma 0 trials
-
Mal de Meleda 0 trials
-
1 sub-type
-
New hope for ALS patients: experimental drug CNM-Au8 now available through expanded access
Disease control Expanded access (paused)This program provides early access to an experimental drug called CNM-Au8 for people with amyotrophic lateral sclerosis (ALS), a progressive nerve disease. Participants must be 18 or older and have a confirmed ALS diagnosis. The goal is to offer treatment to those who cannot join…
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Desperate patient gets experimental stem cells for rare nerve disease
Disease control Expanded access (ended)This study provides an experimental stem cell treatment (HB-adMSCs) to an 83-year-old man with Primary Lateral Sclerosis, a rare nerve disease that causes progressive muscle weakness. The patient's own banked stem cells are used, aiming to slow the disease. This is a single-patie…
Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC